Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2025 02:30 ET | Source: Novartis Pharma AG

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after...